Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib pharmacogenetic association study in Philadelphia chromosome-positive chronic phase chronic myeloid leukemia after relapse or intolerance to prior therapy
2013-004323-37Phase 2Active
- Sponsor
- Fundación PETHEMA
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bosutinib in chronic myelogenous leukemia (CML), sponsored by Fundación PETHEMA. Primary endpoint: Association of single nucleotide polymorphisms with bosutinib activity and toxicity. Started Feb 2015; status: active.
02
Drugs
bosutinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2013-004323-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004323-37.